Tal Medical

The company's business was the development of a non-invasive, neuromodulatory device for the treatment of major depressive disorder and bipolar depression. The device utilized an external electromagnetic coil to apply a time-varying magnetic field to the brain, inducing a much lower electrical field than other neuromodulation technologies. A key differentiator was its potential for rapid action, with studies suggesting mood enhancement in as little as one 20-minute session, a significant departure from antidepressant medications that can take weeks to show effects. The treatment involved a patient lying down with their head positioned inside a 15-inch diameter coil for a 20-minute session, during which they would feel no physical sensation.

Throughout its operation, Tal Medical secured significant funding to support its clinical trials. It raised a total of $14.7 million over three rounds, including a $14 million Series B round in April 2015 led by PureTech Health. The company also received funding from the National Institute of Mental Health (NIMH) to conduct a multi-site clinical trial for its LFMS technology. In 2015, it launched a 120-patient dose optimization trial to assess various dosing regimens. Despite its promising technology and clinical studies, Tal Medical is now considered a deadpooled company.